{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:59:03Z","timestamp":1782845943056,"version":"3.54.5"},"reference-count":45,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Platinum salts are widely used for the treatment of cancers, including head and neck cancers. Despite their efficacy, platinum salts can induce neurosensory disorders such as ototoxicity, tinnitus, and decreased hearing acuity. These side effects can have a major impact on the quality of life of patients and are not often considered after treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The PROTOTOX study aims to compare the quality of life of patients with hearing aids in the case of ototoxicity due to platinum salt-based chemotherapy, according to 2 treatments: standard management without equipment versus standard management with equipment.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The PROTOTOX study is an open pilot prospective monocentric and randomized study executed through collaboration of the Institut de Canc\u00e9rologie de Lorraine (nonprofit comprehensive cancer institute). A total of 52 patients with head and neck cancer undergoing platinum-based chemotherapy and presenting with hypoacusis will be included and followed by an ear, nose, and throat specialist. Audiometric testing will be performed, and eligible participants who consent will be randomized to either receive or not receive hearing aids (groups 1 and 2). The primary endpoint of this study is to compare the quality of life of the patients undergoing platinum-based chemotherapy presenting with hypoacusis according to 2 ways of care: standard care without hearing aid versus standard care with hearing aid. Secondary outcomes are the evaluation of the hearing and the tinnitus, the evaluation of the patients\u2019 satisfaction at the end of the study, and the evaluation of the patients\u2019 adherence to hearing aid in case of ototoxicity due to platinum-based chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study protocol has been opened and is actively recruiting participants. The protocol was launched on November 23, 2023, and data collection is ongoing and will be completed once all patients have completed the protocol. At least 27 patients have been recruited to date. The date of publication of the results is not yet known.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The PROTOTOX study aims at demonstrating that the huge impact of platinum-based chemotherapy on hearing abilities must be managed to maintain the patients\u2019 quality of life. Hearing aid is the solution experimented here.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/71562","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:14:55Z","timestamp":1760127295000},"page":"e71562-e71562","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Study of the Quality of Life of Patients With Ototoxicity Due to Platinum-Based Chemotherapy, With Hearing Aid Versus Those Without: Study Protocol for a Randomized Pilot Study\u2014The PROTOTOX Study"],"prefix":"10.2196","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-9344","authenticated-orcid":false,"given":"Romina","family":"Mastronicola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7522-4400","authenticated-orcid":false,"given":"Elise","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-4071","authenticated-orcid":false,"given":"Yolanda","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-4051","authenticated-orcid":false,"given":"Gilles","family":"Dolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"R1","unstructured":"Accord. cisplatin 1mg\/ml concentrate for solution for infusion\u202f. URL: https:\/\/accord-healthcare-products.co.uk\/products\/c\/cisplatin-solution\/cisplatin-1mgml-concentrate-for-solution-for-infusion [Accessed 30-07-2025]"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08099-8","article-title":"Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting","volume":"22","author":"Paken","journal-title":"BMC Health Serv Res"},{"issue":"1-2","key":"R3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.heares.2006.09.015","article-title":"Mechanisms of cisplatin-induced ototoxicity and prevention","volume":"226","author":"Rybak","journal-title":"Hear Res"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/cncr.29779","article-title":"Ototoxicity and cancer therapy","volume":"122","author":"Landier","journal-title":"Cancer"},{"issue":"4","key":"R5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S2352-4642(21)00020-1","article-title":"Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study","volume":"5","author":"Moke","journal-title":"Lancet Child Adolesc Health"},{"key":"R6","unstructured":"Base-donnees-publique.medicaments. Fiche info - CISPLATINE ACCORD 1 mg\/ml, solution \u00e0 diluer pour perfusion. URL: https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=62426576 [Accessed 20-02-2023]"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1809394","article-title":"Cisplatin-associated ototoxicity: a review for the health professional","volume":"2016","author":"Paken","journal-title":"J Toxicol"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00338","article-title":"Mechanisms of cisplatin-induced ototoxicity and otoprotection","volume":"11","author":"Sheth","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11764-022-01313-w","article-title":"Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy","volume":"17","author":"Sanchez","journal-title":"J Cancer Surviv"},{"issue":"3","key":"R10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1620\/tjem.219.177","article-title":"Cisplatin ototoxicity and protection: clinical and experimental studies","volume":"219","author":"Rybak","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"R11","first-page":"513","volume":"21","author":"Rybak","journal-title":"Am J Otol"},{"issue":"11","key":"R12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14992027.2019.1660918","article-title":"Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review","volume":"58","author":"Pearson","journal-title":"Int J Audiol"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/925485","article-title":"Prevention and restoration of hearing loss associated with the use of cisplatin","volume":"2014","author":"Chirtes","journal-title":"Biomed Res Int"},{"issue":"5","key":"R14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40264-017-0629-8","article-title":"Drug-induced ototoxicity: diagnosis and monitoring","volume":"41","author":"Campbell","journal-title":"Drug Saf"},{"issue":"23","key":"R15","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer","volume":"34","author":"Frisina","journal-title":"J Clin Oncol"},{"issue":"5","key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju044","article-title":"Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics","volume":"106","author":"Travis","journal-title":"J Natl Cancer Inst"},{"key":"R17","unstructured":"Rivi\u00e8re P . Inserm newsroom. Five years after a cancer diagnosis, quality of life and employment status remain strongly impacted. URL: https:\/\/presse.inserm.fr\/en\/five-years-after-a-cancer-diagnosis-quality-of-life-and-employment-status-remain-strongly-impacted\/58347\/ [Accessed 30-07-2025]"},{"issue":"1","key":"R18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11764-022-01314-9","article-title":"The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review","volume":"17","author":"Phillips","journal-title":"J Cancer Surviv"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5935\/0946-5448.20170013","article-title":"Tinnitus patients suffering from anxiety and depression: a review","volume":"21","author":"Ziai","journal-title":"Int Tinnitus J"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2016.03.001","article-title":"Insomnia in patients with chronic tinnitus: cognitive and emotional distress as moderator variables","volume":"83","author":"Cr\u00f6nlein","journal-title":"J Psychosom Res"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/03005364000000114","article-title":"Prediction of quality of life in patients with tinnitus","volume":"34","author":"Erlandsson","journal-title":"Br J Audiol"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00280-019-04012-z","article-title":"Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy","volume":"85","author":"Baguley","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s11764-021-01089-5","article-title":"The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study","volume":"16","author":"Pearson","journal-title":"J Cancer Surviv"},{"key":"R24","unstructured":"Horta AS Dias LN de Jesus LM et al. Quality of life: hearing loss and cancer treatment. Federal University of Sergipe; 2020. URL: https:\/\/www.imedpub.com\/articles-pdfs\/quality-of-life-hearing-loss-and-cancer-treatment.pdf [Accessed 09-01-2025]"},{"issue":"22","key":"R25","doi-asserted-by":"publisher","first-page":"16545","DOI":"10.3390\/ijms242216545","article-title":"Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions","volume":"24","author":"Tan","journal-title":"IJMS"},{"issue":"11","key":"R26","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a033548","article-title":"Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies","volume":"9","author":"Kros","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R27","unstructured":"European medicines agency. ICH E6 Good clinical practice - Scientific guideline. URL: https:\/\/www.ema.europa.eu\/en\/ich-e6-good-clinical-practice-scientific-guideline [Accessed 06-10-2025]"},{"key":"R28","unstructured":"European union agency for fundamental rights. Act n\u00b078-17 of 6 January 1978 on Data Processing, Data Files and Individual Liberties. URL: https:\/\/fra.europa.eu\/en\/law-reference\/act-ndeg78-17-6-january-1978-data-processing-data-files-and-individual-liberties [Accessed 06-10-2025]"},{"key":"R29","unstructured":"WIPO. Law No 2004-800 of August 6, 2004, on Bioethics, France. URL: https:\/\/www.wipo.int\/wipolex\/en\/legislation\/details\/5599 [Accessed 06-10-2025]"},{"key":"R30","unstructured":"I4CT. New Jard\u00e9 decree applying from 17 November 2016 in France. URL: https:\/\/www.iforct.com\/New-Jarde-decree-in-France-News\/p\/3\/665\/0\/ [Accessed 06-10-2025]"},{"key":"R31","unstructured":"Jones day publications. New French Decree Clarifies the Scope of Biomedical Research, Pharmaceutical & Medical Device Update, Vol IV, Issue III. URL: https:\/\/www.jonesday.com\/en\/insights\/2017\/06\/new-french-decree-clarifies-the-scope-of-biomedical-research-ipharmaceutical--medical-device-updatei-vol-iv-issue-iii [Accessed 06-10-2025]"},{"key":"R32","unstructured":"French official gazette. Decree n\u00b0 2017-848 dated 9th May 2017 regarding access to genetic resources and their associated traditional knowledge, as well as the sharing of benefits arisen from their utilisation. URL: www.ecologie.gouv.fr\/sites\/default\/files\/documents\/Decree_9_th_May_2017_French_ABS_regulation.pdf"},{"key":"R33","unstructured":"Iliomad health data. MR-001: The French guideline to conduct a clinical trial in France. URL: https:\/\/www.iliomad.fr\/regulations-and-guidelines\/mr-001-the-french-guideline-to-conduct-a-clinical-trial-in-france [Accessed 06-10-2025]"},{"key":"R34","unstructured":"French business law. French Public Health Code. URL: https:\/\/french-business-law.com\/french-legislation\/legitext000006072665-french-public-health-code\/ [Accessed 06-10-2025]"},{"key":"R35","unstructured":"ChronoL\u00e9gi. Code g\u00e9n\u00e9ral de la propri\u00e9t\u00e9 des personnes publiques. URL: https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000045211903 [Accessed 06-10-2025]"},{"key":"R36","unstructured":"French business law. Article L1122-1-1 of the French Public Health Code. URL: https:\/\/french-business-law.com\/french-legislation-art\/article-l1122-1-1-of-the-french-public-health-code\/ [Accessed 06-10-2025]"},{"issue":"12","key":"R37","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jclinepi.2007.02.006","article-title":"A simple sample size formula for analysis of covariance in randomized clinical trials","volume":"60","author":"Borm","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"R38","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1097\/AUD.0000000000000176","article-title":"Meta-analysis of distortion product otoacoustic emission retest variability for serial monitoring of cochlear function in adults","volume":"36","author":"Reavis","journal-title":"Ear Hear"},{"issue":"6","key":"R39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"Ware","journal-title":"Med Care"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: scoping review","volume":"4","author":"Lins","journal-title":"SAGE Open Med"},{"issue":"11","key":"R41","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0895-4356(98)00093-6","article-title":"The French SF-36 health survey: translation, cultural adaptation and preliminary psychometric evaluation","volume":"51","author":"Lepl\u00e8ge","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"R42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14992027.2017.1286695","article-title":"Coping together with hearing loss: a qualitative meta-synthesis of the psychosocial experiences of people with hearing loss and their communication partners","volume":"56","author":"Barker","journal-title":"Int J Audiol"},{"issue":"11","key":"R43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/14992027.2019.1627010","article-title":"Quality of life in persons with hearing loss: a study of patients referred to an audiological service","volume":"58","author":"Nordvik","journal-title":"Int J Audiol"},{"issue":"4","key":"R44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1055\/s-2008-1043956","article-title":"The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin\u2019s-lymphoma treated within 1984-1993","volume":"209","author":"Urban","journal-title":"Klin Padiatr"},{"issue":"10","key":"R45","first-page":"807","volume":"5","author":"Murphy","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e71562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:01:04Z","timestamp":1782842464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e71562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":45,"URL":"https:\/\/doi.org\/10.2196\/71562","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"v14i1e71562"}}